October 2021 Clinical Review Criteria
Posted on September 30, 2021
Health New England reviews clinical policies and updates accordingly. These policies reside at healthnewengland.org/Providers/Resources. Once on the Resources page, click on Behavioral Health/Medical Policies to learn more.
*Please note, new/revised policies may not appear until closer to the effective date.
|
Medical Policy Title |
Policy Number |
Description of Change |
Effective Date |
LOB Affected |
Policy Type |
||||
| Contact Lenses | UM303POL | · Definitions
Added additional information to Corneal contact lens and Scleral contact lens, and added 4 new definitions · I., General Criteria for Approval o Added Medicare and Commercial to the heading o B., 2.: Removed “MassHealth and” from statement
· III., What is Not Covered: Medicare and Commercial o New (formerly V.) o Updated numbering on sections that follow · IV., Medically Necessary for MassHealth Members o Formerly III. o Letter F. added and 4 statements below it o Added “For additional information:” and the Mass.gov link · VI., What is Not Covered under MassHealth o Added VI., including 7 items · VII., Eyeglasses o Added VII., including 3 items · Added table of HCPCS · Added table of CPT Codes, including statement “NO PA **Covered only when member meets criteria for contact lenses**” · Source/Citation Section o Sources and citations retrieved and updated o Added Medicare Coverage Database citation o Eliminated Yoo, D citation o Added 2 citations re: Absorptive lenses
|
12/1/2021 | Commercial
Medicare Medicaid |
Medical | ||||
| Percutaneous Left Atrial Appendage Closure | UM633POL | · Definitions: Corrected link for CHA2DS2-VASc score
· Source/Citation Section: Confirmed citations and added 2 new citations
|
12/1/2021 | Commercial
Medicare Medicaid |
Medical | ||||
| Azedra
(iobenguane I 131) |
UM726POL | · Definitions: Added to Azedra: “Radioactive therapeutic agent”
· I., Criteria for Approval of Azedra A., 5. was added: “Member has had an administration of inorganic iodine.” · III., What is Not Covered o D. was added: “Members on concomitant drugs that reduce catecholamine uptake or deplete catecholamine stores” o E. was added: “Severe renal impairment (creatinine clearance <30)” · Source/Citation Section: Sources were confirmed and updated.
|
12/1/2021 | Commercial
Medicare Medicaid |
Medical | ||||
| Cochlear Implants, BAHA (Bone-Anchored Hearing Aid), and ABI (Auditory Brainstem Implant) | UM201POL | · Definitions:
Added Unilateral Hearing Loss (UHL), Single-Sided Deafness (SSD), Soundbites; and related definitions · I., Criteria for Approval Changed statement From: Criteria for Approval of Cochlear Implant – for All Lines of Business: To: Criteria for Approval of Initial Cochlear Implant Only (including unilateral hearing loss). See below for information regarding replacement – for All Lines of Business: · II., E. Added the underlined: E., Member displays ANY of the below hearing thresholds: · V., What is Not Covered o Deleted B.: B., Cochlear implantation, including hybrid implants, as a treatment for patients with unilateral hearing loss with or without tinnitus is investigational. o H. was added o I. was added · Source/Citation Section: All citations confirmed · Additional Resources: All confirmed
|
12/1/2021 | Commercial
Medicare Medicaid |
Medical | ||||
| Endothelial Keratoplasty | UM430POL | · CPT Codes: Added “(Confirmed on 5/13/2021 – both are on Y/N list)”
· Source/Citation Section: All confirmed with 1 new one added
|
12/1/2021 | Commercial
Medicare Medicaid |
Medical
|
||||
| Hydrogen Breath Testing (HBT) | UM672POL | · II., Authorization
A.: Added the underlined: “No prior authorization is required for HBT. Policy is in place to support claim-confirmed 5/13/2021 by JS.” · Source/Citation Section: All citations confirmed
|
12/1/2021 | Commercial
Medicare Medicaid |
Medical | ||||
| Corneal Implants (Intrastromal Corneal Ring Segments) | UM687POL | · Definitions: Added Intrastromal Corneal Ring Segments (ICRS)
· Source/Citation Section: All sources and citations were retrieved and confirmed; one new source added.
|
12/1/2021 | Commercial
Medicare Medicaid |
Medical | ||||
| Abdominal Panniculectomy and Removal of Excess Skin | UM238POL | · I., Criteria for Approval: Commercial and Medicare
o Added C.: “The member is 18 years of age or older on the date of services AND” o With the addition of C., the remaining lettering in this section was updated. o E. (formerly D.): Corrected the spelling of the words redundant and subcutaneous · III., Required Documentation Formerly V. including A. thru F. Moved up from further in the document, renamed III. · IV., Criteria for Approval of MassHealth member. Follow link below. (Reviewed on a case-by-case basis) o Formerly III., changed to new IV., MassHealth link added o Deleted residual information under MassHealth criteria: A-J · Former IV. eliminated · CPT Codes: Confirmed all codes on Y/N list · Source/Citation Section o Confirmed all citations o Added: “MassHealth Guidelines for Medical Necessity Determination for Excision of Excessive Skin and Subcutaneous Tissue, Retrieved April 27, 2021, from: https://www.mass.gov/guides/masshealth-guidelines-for-medical-necessity-determination-for-excision-of-excessive-skin-and o Confirmed above link ends with “and”
|
12/1/2021 | Commercial
Medicare Medicaid |
Medical | ||||
| Surgical Management of Morbid Obesity | UM061POL | · I., Criteria for Approval for Ages 18 and Over:
A. o Added the underlined to the 3rd bullet: · “documented enrollment in a program that provides multidisciplinary evaluation and includes behavioral health, nutrition and medical management pre-op within 6 months prior to surgery and post-op” o Added the underlined after 7th bullet after OR: · “evidence of fatty liver disease (non-alcoholic fatty liver disease (NAFLD)” B. Original statement #1. was deleted, with the following statement added in its place: 1. “Documentation from the treating surgeon attesting that the member meets criteria and believes the member is likely to benefit from surgery. AND” · II., Criteria for Approval for Adolescents o Bullet 2: Added “Apnea Hypopnea Index” o Bullet 3: Added “(Non-alcoholic Steatohepatitis)” · III., Repeat Bariatric Surgery E. Added E., “Major surgical complications including anastomotic leak or stricture, band erosion, fistula, stomal stenosis, staple line dehiscence, band slippage, bowel obstruction, GI bleeding, GERD refractory to maximum medical treatment”
· IV., Medicare: o Added “LCD is followed for review.” to the heading o Added Medicare link o Removed statements A., B. and C., and corresponding sub-statements · V., Required Documentation From: Clinical notes referring to all of the above To: Clinical notes documenting all of the above · VI., What is Not Covered F., Added the following 8 bullets · Vertical Banded Gastroplasty (VBG) · Biliopancreatic diversion (BPD) (BMC) · Laparoscopic gastric plication or laparoscopic greater curvature plication · Roux-en-Y gastric bypass (short limb or long limb) combined with simultaneous gastric banding · When used for GERD · Duodenal switch with single anastomosis · Parietal cell separating gastrojejunostomy · Two-stage bariatric surgery procedures · CPT Codes: Added “NO PA” to the following codes:
· Source/Citation Section: All citations confirmed, with 3 added
|
12/1/2021 | Commercial
Medicare Medicaid |
Medical | ||||
| Nodify Lung Nodule Risk Assessment BDX-XL2 (Biodesix, Inc.) | UM751POL | · I., Criteria for Approval Medicare Only:
B.: Corrected the Medicare link · Source/Citation Section: Citations confirmed and corrected if needed (#5)
|
12/1/2021 | Medicare
|
Medical | ||||
| Treatment of Lipodystrophy Syndrome (LDS) | UM389POL | · HCPC Codes and CPT Codes: Confirmed on Y/N list
· Source/Citation Section: Confirmed with 1 new citation added
|
12/1/2021 | Commercial
Medicare Medicaid |
Medical | ||||
| Deep Brain stimulation Treatment for Essential Tremor and Parkinson’s Disease | UM750POL | · I., Criteria for Approval
Added “All Lines of Business” · CPT Codes: o Added “(Confirmed all on Y/N List)” o Deleted “+” in front of code 61864 · Source/Citation Section: Added 3 citations
|
12/1/2021 | Commercial
Medicare Medicaid |
Medical | ||||
| Tumor Treatment Fields (TTFs) (i.e., Optune Device | UM659POL | · I., Criteria for Approval:
o Added “Commercial and MassHealth (Confirmed with Commonwealth Care Alliance)” o A., 2.: added “Temozolomide” · II., (New) o Added II., Criteria for Approval for Medicare – Follow link below: https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=34823 o Former II. changed to III o Former III. changed to IV. · IV., What is Not Covered Added letters I., J., and K. · V., HCPC Code (Former IV.) Code A4555 is removed. · Source/Citation Section: Confirmed, with 4 new citations added
|
12/1/2021 | Commercial
Medicare
|
Medical |







